Rooted in academic excellence, driven by science and generative AI
At Aqemia, we leverage fundamental research to redefine how drugs are discovered. Our mathematics sets us apart. At the core of our approach lies atomic-scale physics, enabling us to uncover truly innovative medicines and deliver hard-to-find therapies.
From solving fundamental equations to molecular invention
Aqemia originates from over 12 years of academic research in theoretical physics conducted at CNRS, Ecole Normale Supérieure, and the Universities of Oxford and Cambridge. This work led to a breakthrough recognized by the American Institute of Physics and resulted in more than 40 peer-reviewed publications.
It laid the groundwork for Aqemia’s proprietary deep physics algorithms, which remove the need for experimental training data and are enhanced by state-of-the-art generative AI to predict drug target affinities in a fast yet accurate way. We combine this with generative AI to rapidly and precisely design novel molecules.
Our approach allows us to initiate programs and optimize molecules across multiple therapeutic areas, scaling drug discovery in a frugal and efficient way to uncover truly innovative solutions for unsolved diseases.
:format(webp))
:format(webp))
Maximilien Levesque
PhD, Prof., CEO and Co-Founder
Maximilien is a physicist with a PhD in quantum physics from CEA Saclay (2010). He conducted postdoctoral research at the Universities of Oxford and Cambridge before returning to École Normale Supérieure (ENS) and CNRS in 2013, where he established a research group in mathematical physics. His work focused on disordered condensed matter and the emergence of collective effects at the mesoscopic scale, from the most basic quantum scale. During his academic career, Maximilien supervised six PhD theses, seven postdoctoral researchers, and authored around 50 scientific articles. His work earned him international awards.
In 2019, Maximilien transitioned from his roles as a full professor and principal investigator to co-found Aqemia with Emmanuelle Martiano-Rolland.
:format(webp))
Emmanuelle Martiano-Rolland
COO and Co-Founder
Before founding Aqemia, Emmanuelle was a Principal at the Boston Consulting Group (BCG), where she led numerous projects for executive teams of pharmaceutical companies and B2B software firms across Europe and Asia. Her work focused primarily on innovation management and pricing strategies. Emmanuelle holds an engineering degree from CentraleSupélec (France) and a Master of Science from Imperial College London.
In 2019, Emmanuelle co-founded Aqemia with Maximilien Levesque, bringing her expertise in business and organizational strategy to support Aqemia’s groundbreaking approach to scale drug discovery.